Effectivenes of Siddha Supplement MAM Granules in the Management of Pre Symptomatic COVID 19 patients
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/02/031420
- Lead Sponsor
- Central Council for Research in Siddha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Laboratory Confirmed COVID â?? 19 with Asymptomatic Patient (as per ICMR Guidelines) 30 Patients in each group
2. Aged 18-65 years
3. Consenting to participate in the study and sign the informed consent
1.Patients with severe primary respiratory disease or other pathogenic microbial pneumonia
2.Patient with Uncontrolled DM (>= 350 mgs Fasting Sugar) Severe HT (180/120 mmHg as per JNC 8 Guidelines), Chronic BA (>= 5 years Based on Clinical History), Renal Dysfunction (Known CKD >= 5 years eGFR Stage >= 3 as per NKA guidelines)
3.Pregnant and Lactating mothers
4.People who have history of allergic to Siddha medicine or intolerant to taking medication
5.Patients participating in other COVID-19 clinical trials
6.Patients already went under COVID 19 vaccination
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in incidence of clinical symptoms like fever, cough and breathlessness <br/ ><br>Negative conversion of SARS CoV - 2 by 14 days <br/ ><br>Reduction in Viral load of SARS CoV â?? 2 at the end of treatment <br/ ><br>Effect of drugs inflammatory markers (IL6) and other Immunity Markers at the end of treatment. <br/ ><br>Timepoint: 14 days
- Secondary Outcome Measures
Name Time Method Reduction in incidence of complications (ARDS, other systematic complications) <br/ ><br>Laboratory markers (Hematological & Bio â?? Chemical Markers) <br/ ><br>Adverse events/effects Siddha-based measurements <br/ ><br>Siddha Udaliyal assessment by using YI Tool <br/ ><br>Timepoint: 14 Days